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Background: The clinical course for hematologic malignancy varies widely and no prognostic tool is available for
patients with a hematologic malignancy under palliative care. To assess the application of the Palliative Prognostic
Index (PPI), Charlson Comorbidity Index (CCI), and Glasgow Prognostic Score (GPS) as prognostic tools in patients
with hematologic malignancies under palliative care.
Methods: We included 217 patients with pathologically proven hematologic malignancies under palliative care
consultation service (PCCS) between January 2006 and December 2012 at a single medical center in Taiwan.
Patients were categorized into subgroups by PPI, CCI, and GPS for survival analysis.
Results: The median survival was 16 days (interquartile range, 4–47.5 days) for all patients and 204 patients (94%)
died within 180 days after PCCS. There was a significant difference in survival among patients categorized using the
PPI (median survival 49, 15, and 7 days in patients categorized into a good, intermittent, and poor prognostic
group, respectively) and the GPS (median survival 66 and 13 days for GPS 0 and 1, respectively). There was no
difference in survival between patients with a GPS score of 0 versus 2, or a CCI score of 0 versus ≥1. The survival
time was significantly discriminated after stratifying patients with a good PPI score based on the CCI (median
survival 102 and 41 days in patients with a CCI score of 0 and ≥1, respectively) from those with a poor PPI score by
using the GPS (median survival 47 and 7 days in patients with GPS scores of 0 and 1–2, respectively).
Conclusions: PPI is a useful prognosticator of life expectancy in terminally ill patients under palliative care for a
hematologic malignancy. Concurrent use of the GPS and CCI improved the accuracy of prognostication using the
PPI.
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Hematologic malignancies are distinct from solid can-
cers; they are characterized by disseminated tumor in-
volvement and usually present with symptoms related to
bone marrow failure such as infection, bleeding, and
anemia, rather than direct compression by a solid tumor
[1]. Hematologic malignancies are also relatively rare, ac-
counting for less than 5% of total cancer deaths in
Taiwan annually [2].
Several prognostic scores for predicting patient sur-
vival have been developed, based on clinical features, as-
sociated comorbidity, and laboratory data. Three of most
widely used scores for predicting life expectancy of can-
cer patients are the Palliative Prognostic Index (PPI)
[3-6], the Charlson Comorbidity Index (CCI) [7-12], and
the Glasgow Prognostic Score (GPS) [13]. The PPI is
used to predict life expectancy in terminally ill cancer
patients under palliative care and is scored by presenta-
tion of clinical features on the day of palliative care re-
ferral [3]. The PPI has been validated in different
hospice settings without reference to a particular cancer
type [4-6]. The application of the PPI as a prognosticator
in patients with a given cancer type is uncertain. The
CCI is based on 1-year mortality data from internal
medicine patients admitted to an inpatient setting and is
the most widely used comorbidity index in cancer pa-
tients [7,8]. The CCI has been widely used as a predictor
and validated for patients with hematologic malignancies
and who are undergoing antitumor therapy [9-12]. The
role of the CCI in the palliative care setting has not been
investigated. GPS, combining serum C-reactive protein
(CRP) and albumin levels, is an inflammation based-
prognostic score and has been demonstrated to have
independent prognostic for solid cancer patients with
operative or inoperative disease, and those undergoing
chemotherapy [13]. However, there is little data regard-
ing the role of GPS as a prognosticator in patients with
hematologic malignancy.
Because no prognostic tool was available for patients
with a hematologic malignancy under palliative care, we
retrospectively analyzed the clinical characteristics of
these patients, who were under the palliative care con-
sultation service (PCCS) at a medical center in Taiwan.
We wished to assess the application of the PPI, CCI, and
GPS as prognostic tools in terminally ill patients with a
hematologic malignancy under the care of PCCS.
Methods
Patient selection
A cohort of 4685 terminally ill cancer patients who received
care from PCCS between January 2006 and December
2011 at a single medical center in Taiwan (Chang Gung
Memorial Hospital at Linkou) was recorded in our data-
base. All the patients were referred to PCCS because theirclinician judged that they would benefit from palliative care
and were unlikely to survive longer than 6 months. Among
these patients, 230 (4.9%) had a pathological-proven
hematologic malignancy and were included in this study.
Thirteen patients were excluded because of an incomplete
record of GPS components, and the remaining 217 patients
were enrolled for survival analysis. The study protocol was
ed by the Institutional Review Board of the Chang Gung
Memorial Hospital (#101-1980B), in compliance with the
Helsinki Declaration (1996). Written informed consent was
obtained from all patients before receiving the PCCS.
Data collection
Patient demographics, including age, gender, and diagno-
ses of hematologic malignancy (lymphoma, leukemia or
multiple myeloma) were recorded at the first consultation
by a specialist nurse using a formulated “patient record
form” developed by the Bureau of Health Promotion and
based on the clinical experience of terminal cancer in
Taiwan [14]. The “patient record form” consisted of the
Eastern Cooperative Oncology Group performance status
(ECOG PS) and 29 distress symptoms assessed by the
patient including dyspnea, edema, delirium, and loss of
appetite, as well as the amount of food and fluids they
had taken orally. The physical symptoms of patients
were recorded by a palliative care physician or nurse
specialist using the same form at each PCCS visit. Patients
were evaluated to establish the presence or absence of
each physical symptom. If patients were receiving total
parental nutrition or had an enteral feeding tube, they
were included in a “normal” oral intake category. Delirium
was diagnosed using the criteria of the Diagnostic and
Statistical Manual of Mental Disorders (Fourth Edition).
For patients who had difficulty with verbal communica-
tion, a nurse specialist assessed their status using a proxy
or caregiver response.
The PPI is the sum of the Palliative Performance Scale
(PPS) [15] and scores for 4 other clinical variables: oral
intake, edema, resting dyspnea, and delirium, giving a
number between 0 and 15. The PPI was calculated for
each patient using the “patient record form” filled in on
the day that PCCS took over their care. To simplify PPI
calculations, we used the ECOG PS instead of the PPS,
where the ECOG PS scale scores of 0–2, 3, and 4 corre-
sponded to PPS scores of 100–60, 30–50, and 10–20, re-
spectively [16]. Any comorbidity when PCCS took over
care were obtained retrospectively from the patient’s
electronic chart. A modified CCI, which has been vali-
dated for patients with hematologic malignancies, was
scored according to the patient’s comorbidity [9]. The
CRP and albumin levels within 14 days of the patient’s
care being taken over by PCCS were retrospectively ob-
tained from the electronic chart and were used to calcu-
late the GPS. The survival time was defined from the
Table 1 Baseline patient demographic data
Patient characteristics (n = 217) Number (%)







Origin of primary tumor
Leukemia 131 (60.4)
Lymphoma 66 (30.4)
Multiple myeloma 20 (9.2)
Core components and scoring of PPI
ECOG performance status 0–2 (score 0) 36 (16.6)
ECOG performance status 3 (score 2.5) 58 (26.7)
ECOG performance status 4 (score 4) 123 (56.7)
No dyspnea (score 0) 91 (41.9)
Dyspnea at rest (score 3.5) 126 (58.1)
No delirium (score 0) 187 (86.2)
Delirium present (score 4) 30 (13.8)
No edema (score 0) 168 (77.4)
Edema present (score 1) 49 (22.6)
Oral intake normal (score 0) 115 (53.0)
Oral intake reduced but more than one mouthful
(score 1)
87 (40.1)
Oral intake less than one mouthful (score 2.5) 15 (6.9)
Total PPI score, median (IQR) 7 (4–8.5)
Components and scoring of GPS
CRP >10 (score 1) 181 (83.4)
Albumin <3.5 (score 1) 156 (71.9)
Total GPS score, median (IQR) 2 (1–2)
Core comorbidity and scoring of CCI
Myocardial infarction (score 1) 8 (3.7)
Congestive heart failure (score 1) 5 (2.3)
Cerebral vascular disease (score 1) 7 (3.2)
Peptic ulcer (score 1) 22 (10.1)
Hepatic disease, mild (score 1) 32 (14.7)
Diabetes, mild or moderate, score (1) 20 (9.2)
Pulmonary disease, moderate or severe (score 1) 5 (2.3)
Connective tissue disease (score 1) 9 (4.1)
Diabetes, severe with end-organ damage (score 2) 24 (11.1)
Renal disease, moderate or severe (score 2) 6 (2.8)
Solid tumor, without metastases (score 2) 7 (3.2)
Hepatic disease, moderate or severe (score 3) 6 (2.8)
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outpatients, the date of death was obtained from either
the cancer registration center in our institute or the Na-
tional Register of Death Database in Taiwan. Surviving
patients were censored 180 days from the first day of
PCCS referral.
Statistical analysis
Basic demographic data were summarized as n (%) for cat-
egorical variables, and the median with the interquartile
range (IQRs, 25–75%) for continuous variables, respect-
ively. Patients were stratified into subgroups on the basis
of the PPI, GPS, and CCI for survival analysis. For the PPI,
patients were divided into good (score 0–4), intermediate
(score 4.5–6) and poor prognostic groups (score >6) ac-
cording to the PPI score, using the same categories as our
previous reports [6]. Patients were divided into good
(score 0), intermediate (score 1), and poor prognostic
groups (score 2) on the basis of GPS. Due to the wide vari-
ation in the CCI among our patients (range, 0–12; IQR,
0–2), they were divided into good (CCI = 0) and poor
prognostic groups (CCI ≥ 1), using the optimal cut-off cat-
egories of the CCI, which were selected with the intent of
generating preliminary data with a better intra-group dif-
ference in survival time. Patients in different PPI groups
were further stratified by their GPS and CCI scores with
the intention to evaluate their prognostic value in each dif-
ferent PPI group. Overall survival was calculated using the
Kaplan-Meier method. Log-rank tests were used to deter-
mine the significant differences between the survival
curves. Hazard ratios (HRs) for subgroup categories with
respect to the PPI, GPS, and CCI were estimated using
multivariate Cox regression after adjusting for age, gender,
and type of hematologic malignancy, which were also ad-
justed to minimize bias from care received from other
sources. Statistical analyses were performed using SPSS
17.0 statistics software (SPSS Inc, Chicago, IL, USA). All
statistical assessments were considered significant when
P < 0.05.
Results
Table 1 shows the patient demographic data, and the
prevalence rate of core components that constitute the
PPI, GPS, and CCI of the 217 patients. The median pa-
tient age was 63.3 years (IQR, 46–76 years) and 61.3% of
the patients were men. Acute leukemia was the most
common disease (131 patients, 60.4%), followed by
lymphoma (66 patients, 30.4%) and multiple myeloma
(20 patients, 9.2%). The median survival time was 16 days
(IQR, 4–47.5 days). At the end of the follow up period,
204 patients (94%) had died, and 13 patients (6%) had
survived for more than 180 days.
The death rate and survival time with respect to PPI,
GPS, and CCI categories are given in Table 2. The death
Table 1 Baseline patient demographic data (Continued)
Solid cancer, with metastases (score 6) 2 (0.9)
Total CCI score, median (IQR) 0 (0–2)
Died before the end of follow up 204 (94.0)
IQR, interquartile range; PPI, Palliative Prognostic Index; ECOG, Eastern
Cooperative Oncology Group; GPS, Glasgow Prognostic Score; CRP, C-reactive
protein; CCI, Charlson Comorbidity Index.
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groups was 84.6%, 90.9%, and 98.5%, respectively, and
the median survival time was 49 days, 15 days, and
7 days (Figure 1a), respectively. The adjusted hazard ra-
tion (HR) was 1.73 (95% confidence interval [CI], 1.07–
2.80, p = 0.026) when comparing the intermittent and
good prognostic groups, and 3.40 (95% CI, 2.31–4.98,
p < 0.001) when comparing the poor and good prognostic
groups.
On the basis of the GPS, 6.9%, 30.9%, and 62.2% of
patients were in the good, intermediate, and poor prog-
nostic groups, in which the death rate was 93.3%,
89.3%, and 95.9% and median survival was 66, 11, and
17 days (Figure 1b), respectively. The adjusted HR was
2.12 (95% CI, 1.13–3.97; p = 0.020) when comparing
the intermittent and good prognostic groups, and 1.71
(95% CI, 0.96–3.05; p = 0.069) when comparing the
poor and good prognostic groups.
The CCI scores assigned 52.5% and 47.5% of patients
to the good (CCI = 0) and poor (CCI ≥1) prognostic
groups, respectively, in which the death rate was 90.4%
and 98.1%, and the median survival time was 17 and 14,
respectively (Figure 1c). There was no significant differ-
ence in survival between these two patient groups after
adjusting for covariates.
Patients categorized into different PPI groups were
further stratified by the GPS and CCI scores for survivalTable 2 Survival and death rates based on Palliative Prognos
Charlson Comorbidity Index (CCI) categories
Patient groups and categories No. (%) No. deaths (%)
All patients 217(100) 204(94.0)
PPI
Good prognosis (score 0–4) 52 (24.0) 44 (84.6)
Intermediate prognosis (score 4.5–6.0) 33 (15.2) 30 (90.9)
Poor prognosis (score > 6) 132 (60.8) 130 (98.5)
GPS
Good prognosis (score 0) 15 (6.9) 14 (93.3)
Intermediate prognosis (score 1) 56 (30.9) 50 (89.3)
Poor prognosis (score 2) 146 (62.2) 140 (95.9)
CCI
Good prognosis (score 0) 114 (52.5) 103 (90.4)
Poor prognosis (score≥ 1) 103 (47.5) 101 (98.1)analysis (Table 3). For patients in the good PPI prognos-
tic group, the death rate was 69.2% and 100%, and the
median survival time was 102 and 41 days for those with
CCI scores of 0 and ≥ 1, respectively (Figure 2). The ad-
justed HR was 13.0 (95% CI, 4.7–35.9; p < 0.001) when
comparing the CCI score 0 and CCI score ≥ 1 groups.
Stratification by the CCI had no effect on survival time
for patients in the intermediate or poor PPI prognosis
group. For patients in the poor PPI prognostic group,
the death rate was 88.9% and 99.2%, and the median sur-
vival time was 47 and 7 days for patients with a GPS
score 0 and GPS score 1–2, respectively (Figure 3). The
adjusted HR was 2.66 (95% CI, 1.23–5.75; p = 0.013)
when comparing with a GPS score 0 and score 1–2
groups.
Discussion
Our findings show that the PPI, but not the GPS or CCI,
have significant predictive value for the life expectancy
of terminally ill patients with hematologic malignancies
under palliative care. To the best of our knowledge, this
study was the first to establish the PPI as a prognostica-
tor of life expectancy in these patients. Adding the CCI
in good the PPI prognostic group helps to identify pa-
tients likely to have less favorable outcomes; while add-
ing the GPS in the poor PPI prognostic group increases
the accuracy to distinguish those less likely to have the
poorest outcomes. The use of these tools might enable
health workers to provide more appropriate end-of-life
care for the patient, and to refer patients to palliative
care earlier. Patients and their families might then also
have adequate time to discuss end-of-life issues, and to
prepare for the patient’s death.
The PPI assessment for predicting survival had two






16 (11.4–21.4) - –
49 (38.4–59.6) 1 reference
15 (9.3-20.6) 1.73 (1.07–2.80) 0.026
7 (4.7–9.3) 3.40 (2.31–4.98) <0.001
66 (0–140.5) 1 reference
11 (1.5–20.4) 2.12 (1.13–3.97) 0.020
17 (12.8–21.2) 1.71 (0.964–3.05) 0.069
17 (12.6–21.4) 1 reference
14 (7.7–20.3) 1.11 (0.82–1.50) 0.51
Figure 1 Median patient survival according to (1a) Palliative Prognostic
Index (PPI) based good (score 0–4, solid line), intermediate (score 4.5–6,
fine dashed line), and poor (score >6, coarse dashed line) prognostic
groups; (1b) Glasgow Prognostic Score (GPS) based good (score 0, solid
line), intermediate (score 1, coarse dashed line), and poor (score 2, fine
dashed line) prognostic groups; (1c) Charlson Comorbidy Index (CCI)
based good (score 0, solid line) and poor (score ≥1, fine dashed group)
prognostic groups.
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to account for subsequent changes in the patient’s condi-
tion or their clinical course. Therefore, a single PPI score
may not be an appropriate predictor of long-term survival
in terminally ill patients. The combination of the initial
PPI with subsequent changes in the PPI might solve this
problem [17,18]. The second difficulty is that the PPI is
based only on clinical features (performance status, dys-
pnea, oral intake, edema and delirium) without regard to
comorbidity and nutritional status. Dying patients, regard-
less of their underlying diseases, often had clusters of PPI
symptoms [19]. Identifying these core symptoms can help
clinicians estimate a patient’s life expectancy. The PPI is
simple to use for this reason, but also has limited clinical
application because it is difficult to make further survival
predictions for patients with similar scores. Moreover, it is
almost impossible to further stratify patients in the good
PPI prognostic group because they may be virtually free of
any of these core symptoms. By combining it with the CCI
and GPS, as in the present study, a better discrimination
of survival in patients categorized into the same prognos-
tic group by the PPI is possible.
The CRP is an acute-phase protein recognized as a
marker of systemic inflammation [20]. Albumin repre-
sents a marker of nutritional status and hypoalbumin-
emia might reflect malnutrition or declining health
status [21]. The GPS, based on CRP and albumin levels,
has been demonstrated to have prognostic value in a
wide range of solid cancers since it was first proposed in
2003 [22]. There were significant differences in survival
among GPS scores of 0, 1 and 2 in patients with meta-
static colorectal cancers treated with bevacizumab or
anti-EGFR therapy [23,24]. The prognostic value of the
GPS in other hematologic malignancies or in patients
with a hematologic malignancy under palliative care has
never been investigated, and ours is the first study to as-
sess the latter. Although our findings show that the GPS
was an independent prognostic factor when comparing
the score 0 and score 1 groups, the difference in survival
between the score 0 and score 2 groups was only of bor-
derline significance (p = 0.069). This may be because the
statistical analysis was limited by the small number of
patients, as only 6.9% of patients were in the GPS score
0 group. In addition, there was no significant difference
in survival between patients of GPS 1 and 2. This may
be due to the very short overall survival (median survival
of 16 days) in these groups. Importantly, our study
showed that low CRP levels and normal albumin levels
are significant positive prognostic factors, especially in
patients presenting with multiple negative clinical features
(PPI score > 6).
The CCI is the most commonly used comorbidity
index [7-12]. Initially, the CCI was to assess the role of
comorbidity on mortality risks in longitudinal studies
Table 3 Subgroup analysis for survival based on the Glasgow Prognostic Score (GPS), and Charlson Comorbidity Index










Good prognosis (total score 0–4) GPS score 0 4 (1.8) 4 (100) 70 (48.4–91.6) 1 0.62
GPS score 1-2 48 (22.1) 40 (83.3) 49 (72.8–105.2) 1.32 (0.44–3.97)
CCI score 0 26 (12.0) 18 (69.2) 102 (49.5–154.5) 1 <0.001
CCI score≥ 1 26 (12.0) 26 (100) 41 (36.0–45.9) 13.0 (4.7–35.9)
Intermediate prognosis (total score 4.5–6) GPS score 0 2 (0.9) 2 (100) 6 1 0.22
GPS score 1–2 31 (14.3) 28 (90.3) 16 (10.6–21.4) 0.36 (0.07–1.88)
CCI score 0 19 (8.8) 17 (89.5) 16 (0–31.6) 1 0.80
CCI score ≥1 14 (6.5) 13 (92.9) 10 (7.5–12.4) 1.14 (0.40–3.26)
Poor prognosis (total score >6) GPS score 0 9 (4.1) 8 (88.9) 47 (0–152) 1 0.013
GPS score 1–2 123 (56.7) 122 (99.2) 7 (4.7–9.3) 2.66 (1.23–5.75)
CCI score 0 69 (31.8) 68 (98.6) 7 (1.9–12.1) 1 0.21
CCI score ≥1 63 (29.0) 62 (98.4) 7 (4.1–9.9) 0.72 (0.49–1.07)
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come in patients with hematologic malignancies who are
undergoing hematopoietic stem cell transplantation [9] or
antitumor therapy [10-12]. CCI is also associated with more
frequent hospital mortality in patients with hematologic
malignancies who were admitted to the intensive care unit
[25]. We previously showed that patients with hematologic
malignancies were younger than those with solid cancers
[1]. This may explains why more than half of our patients
presented with a CCI score 0. In order to evaluate how co-
morbidities impacted survival, we used a modified CCI [9],
excluding age and hematologic malignancies from its ori-
ginal designation [26]. We showed that comorbidities had
little impact on survival in terminally ill hematologic malig-
nancies patients. However, CCI may still be a prognostica-
tor in patients in the good PPI prognostic group.Figure 2 Subgroup survival analysis with respect to Glasgow
Prognostic Score (GPS) in the PPI poor prognostic group (solid line,
GPS 0; fine dashed line, GPS 1–2).The strength of this study was in the large number
of patients with a hematologic malignancy under pal-
liative care. However, this was a retrospective, single-
institute study, and the timing of the CRP and albumin
measurements was not planned in advance, thereby
introducing the possibility of bias. The prognostic
value of the PPI, GPS, and CCI in terminally ill pa-
tients with hematologic malignancies under or not
under palliative care needs further prospective explor-
ation and validation.Conclusions
PPI is a useful prognosticator of life expectancy in ter-
minally ill patients with a hematologic malignancy under
palliative care. Concurrent use of the GPS and CCI im-
proved the accuracy of prognostication using the PPI.Figure 3 Subgroup survival analysis with respect to Charlson
Comorbidity Index (CCI) in the PPI good prognostic group (solid
line, CCI score 0; fine dashed line, CCI score ≥1).
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